All News CStone Pharmaceuticals

Equities

2616

KYG2588M1006

Market Closed - Hong Kong S.E. Other stock markets 04:08:16 2024-04-24 am EDT			5-day change	1st Jan Change
0.92 ^HKD	+6.98%		+6.98%	-59.47%

09:58am	Cstone Pharmaceuticals Logs Lower Loss for 2023, Shares Up By Nearly 5%	MT
Apr. 23	CStone Pharmaceuticals Reports Earnings Results for the Full Year Ended December 31, 2023	CI

All News

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Cstone Pharmaceuticals Logs Lower Loss for 2023, Shares Up By Nearly 5%	03:58am	MT
CStone Pharmaceuticals Reports Earnings Results for the Full Year Ended December 31, 2023	Apr. 23	CI
China Accepts CStone Pharmaceuticals' Manufacturing Application for RET Inhibitor	Apr. 08	MT
CStone Announces the Availability of RET Inhibitor GAVRETO® Manufacturing Localization Application by Center for Drug Evalence of China NMPA	Apr. 08	CI
Cstone Pharmaceuticals Cancer Drug Gets Supplemental Biologics License Application Approved	Mar. 15	MT
CStone Pharmaceuticals Announces the Fifth Indication Approved for Sugemalimab in China as First-Line Treatment for Gastric Cancer	Mar. 15	CI
CStone Pharmaceuticals Booted From Hong Kong Stock Connect; Shares Plunge 25%	Mar. 04	MT
CStone sells to Servier its exclusive rights to TIBSOVO in Greater China and Singapore	Dec. 22	AQ
CStone Pharmaceuticals Arm to Sell Ivosidenib Business for $50 Million	Dec. 21	MT
The Servier Group agreed to acquire CStone Pharmaceuticals, Exclusive rights to TIBSOVO® in Greater China and Singapore from CStone Pharmaceuticals for $44 million.	Dec. 20	CI
China Includes CStone's Gastrointestinal Stromal Tumor Treatment in National Reimbursement List; Shares Jump 6%	Dec. 13	MT
CStone Announces NMPA Approval of Sugemalimab as First-line Treatment for Esophageal Squamous Cell Carcinoma	Dec. 11	AQ
China Approves CStone Pharma's Treatment for Esophageal Squamous Cell Carcinoma; Shares Soar 21%	Dec. 08	MT
CStone Pharmaceuticals Announces NMPA Approval of Sugemalimab as First-Line Treatment for Esophageal Squamous Cell Carcinoma	Dec. 07	CI
3SBio Secures Exclusive License to CStone's Anti-Tumor Drug in China	Nov. 02	MT
CStone Pharmaceuticals Announces Strategic Partnership and Exclusive Licensing Agreement with Shenyang Sunshine Pharmaceuticals Co., Ltd for Nofazinlimab (Anti-PD-1 Antibody) in Mainland China	Nov. 01	CI
CStone Announces Strategic Partnership and Exclusive Licensing Agreement with 3Sbio for Nofazinlimab (ANTI-PD-1 Antibody) in Mainland China	Nov. 01	CI
CStone Pharmaceuticals Announces NMPA Approval of Sugemalimab for Patients with Relapsed or Refractory Extranodal NK/T-cell Lymphoma	23-10-30	CI
China Approves CStone's Lymphoma Medication	23-10-30	MT
CStone Pharmaceutical Awaits Chinese Approval for Anti-Cancer Drug	23-10-24	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

All News CStone Pharmaceuticals

Equities

2616

KYG2588M1006

All News

Filters